Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
Abstract Background Marzeptacog alfa (activated) (MarzAA), a novel recombinant activated human factor VII (FVIIa) variant, was developed to provide increased procoagulant activity, subcutaneous (SC) administration, and longer duration of action in people with hemophilia. Objectives To investigate if...
Main Authors: | Johnny Mahlangu, Howard Levy, Marina V. Kosinova, Heghine Khachatryan, Bartosz Korczowski, Levani Makhaldiani, Genadi Iosava, Martin Lee, Frank Del Greco |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-08-01
|
Series: | Research and Practice in Thrombosis and Haemostasis |
Subjects: | |
Online Access: | https://doi.org/10.1002/rth2.12576 |
Similar Items
-
Origin and Role of Factor Viia
by: Khandekar, Gauri
Published: (2013) -
BUDGET IMPACT ANALYSIS OF INHIBITOR HAEMOPHILIA A THERAPY WITH BYPASSING AGENTS
by: Konstantin Tachkov, et al.
Published: (2019-04-01) -
HEMOPHILIA INHIBITOR PATIENTS: THE USE OF RECOMBINANT FACTOR VIIa
by: Dušan Andoljšek, et al.
Published: (2004-12-01) -
Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence
by: Linari S, et al.
Published: (2020-05-01) -
The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study
by: Nina Haagenrud Schultz, et al.
Published: (2021-07-01)